Provided by Tiger Trade Technology Pte. Ltd.

Orchestra BioMed

6.08
+0.30005.19%
Post-market: 6.200.1200+1.97%16:20 EDT
Volume:1.14M
Turnover:6.87M
Market Cap:364.07M
PE:-6.08
High:6.30
Open:5.74
Low:5.71
Close:5.78
52wk High:6.30
52wk Low:2.20
Shares:59.88M
Float Shares:33.00M
Volume Ratio:3.18
T/O Rate:3.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9995
EPS(LYR):-1.1091
ROE:-397.30%
ROA:-45.73%
PB:18.84
PE(LYR):-5.48

Loading ...

Orchestra BioMed posts investor deck spotlighting pivotal-stage AVIM hypertension therapy and Virtue sirolimus balloon program

Reuters
·
Jun 04

Orchestra BioMed CEO, Chair David P. Hochman acquires 5,000 common shares worth $19,150

Reuters
·
Jun 03

Orchestra BioMed COO Darren Sherman disposes of 15,000 common shares worth $58,050

Reuters
·
Jun 03

Orchestra BioMed grants options for 85,500 shares to five new hires under inducement plan

Reuters
·
Jun 03

Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 03

Top Brass Double Down on Orchestra BioMed as Insider Buying Heats Up

TIPRANKS
·
May 20

Orchestra BioMed Holdings Is Maintained at Buy by B. Riley Securities

Dow Jones
·
May 20

Orchestra BioMed CEO joins Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 19

Orchestra BioMed CEO, Chair David Hochman buys 5,000 shares for $18,850

Reuters
·
May 19

Orchestra BioMed director Aryeh Jason buys 8,971 shares valued at $34,986.9

Reuters
·
May 19

B. Riley Cuts Price Target on Orchestra BioMed Holdings to $10 From $12, Keeps Buy Rating

MT Newswires Live
·
May 19

Orchestra BioMed director Eric S. Fain acquires 20,000 shares worth $82,600

Reuters
·
May 18

Orchestra BioMed releases corporate presentation on pivotal-stage AVIM hypertension and Virtue SAB programs

Reuters
·
May 14

Orchestra BioMed Holdings Is Maintained at Overweight by Barclays

Dow Jones
·
May 13

Orchestra BioMed price target raised to $13 from $12 at Barclays

TIPRANKS
·
May 13

Orchestra BioMed reports Q1 EPS (33c), consensus (44c)

TIPRANKS
·
May 13

Orchestra Biomed Holdings Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Orchestra BioMed Hldgs Q1 EPS $(0.33) Beats $(0.41) Estimate, Sales $110.000K Miss $190.750K Estimate

Benzinga Earnings
·
May 13

Orchestra BioMed Q1 revenue falls and misses estimates

Reuters
·
May 13

BRIEF-Orchestra BioMed Q1 EPS USD -0.33

Reuters
·
May 13